Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon alpha-2a in the treatment of chronic hepatitis C.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples